(Q33601710)

English

Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

based on heuristic

inferred from title

Martin S. Tallman

11

object named as

Martin S Tallman

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Hillard M. Lazarus

5

object named as

Hillard M Lazarus

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

2

object named as

Megan Othus

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Elisabeth Paietta

8

object named as

Elisabeth M Paietta

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1

object named as

Mark R Litzow

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

Larry D Cripe

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Steven D Gore

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sandra J Lee

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

John M Bennett

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Gordon W Dewald

9

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Jacob M Rowe

10

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Eastern Cooperative Oncology Group Leukemia Committee

12

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

language of work or name

0 references

publication date

5 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

148

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

217-225

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

The therapy of relapsed acute leukaemia in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

Topotecan in combination chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

Design and analysis of trials of salvage therapy in acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

14 July 2018

Del (9q) AML: clinical and cytological characteristics and prognostic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

30 October 2018

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

30 October 2018

Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

30 October 2018

Safety of high-dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

30 October 2018

Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

30 October 2018

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

30 October 2018

Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

30 October 2018

Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

30 October 2018

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2809127

30 October 2018

IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/19804455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations

1 reference

https://pubmed.ncbi.nlm.nih.gov/19804455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19804455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of liposomal daunorubicin in patients with acute leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19804455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19804455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Liposome encapsulated daunorubicin (daunoxome) for acute leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19804455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/19804455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19804455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of normal myeloid-associated antigens by acute leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19804455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as FAB-M3 acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19804455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute myeloid leukaemia expressing the leucocyte integrin CD11b-a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Eastern Cooperative Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19804455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New agents for the treatment of acute myelogenous leukemia: focus on topotecan and retinoids

1 reference

https://pubmed.ncbi.nlm.nih.gov/19804455

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2141.2009.07917.X

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33601710&oldid=1995990637"